CTIS2023-508949-40-00进行中（未招募）1 期
A multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 2 trial to evaluate the efficacy and safety of BP1.7881 in adult patients with eosinophilic esophagitis. - P22-04 / BP1.7881
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Written informed consent obtained prior to any trial-related procedures., Male or female =18 years old., Presence of EoE associated symptoms at least during the last 4 weeks prior to screening (e.g., symptoms may include dysphagia which require liquids, coughing or gagging, vomiting, or medical attention to obtain relief)., A diagnosis of EoE confirmed at screening., To the opinion of the investigator the patient will be compliant to carry out the trial procedures, including both esophagogastroduodenoscopies with biopsies., Patients must have a cooperative attitude and be able to comply with the entire trial requirements and procedures (e.g., trial-related questionnaire, drug compliance, not use prohibited concomitant medications)., Female patients: post-menopausal women having at least 12 months of natural (spontaneous) amenorrhea, or women of childbearing potential (WOCBP, defined as all women physiologically capable of becoming pregnant) using a highly effective method of contraception* for the duration of the trial and for one month after stopping the investigational medication., If required, patient must be insured by appropriate national health insurance system.
排除标准
- •Patient with any of the following disease: documented gastroesophageal reflux disease (note: reflux associated with EoE is not exclusionary), recurrent vomiting due to causes other than EoE, parasitic and fungal infections of the gastrointestinal tract, congenital esophageal rings, Crohn’s disease, periarteritis, allergic vasculitis, drug injury, connective tissue diseases, bullous pemphigoid, pemphigoid vegetans, graft-versus-host disease, achalasia, celiac disease, vasculitis, carcinoma of the esophagus., History of significant cardiovascular disease, particularly recent history of myocardial infarction or unstable coronary artery disease, arrhythmias, congestive heart failure, uncontrolled arterial hypertension. Patient with a known history of long QT syndrome with or without history of syncope., Patient with a clinically significant deviation(s) from normal on 12-lead ECG that results in an active medical problem, as determined by the Investigator at screening or has a corrected QT interval using Fridericia’s formula (QTcF) =450 msec for males or =470 msec for females., Patient with unstable concurrent disease including: uncontrolled hyperthyroidism or other endocrine disease, uncontrolled gastrointestinal disease (e.g. active peptic ulcer), uncontrolled hematological disease, uncontrolled autoimmune disorders, or other that might affect the patient’s safety and/or interfere with the conduct of the study according to the Investigator’s judgement., Patient with known or history of malignancy within the past 5 years with the exception of adequately treated or excised non metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ., Established diagnosis of human immunodeficiency virus (HIV), hepatitis B viral infection or is positive for hepatitis surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) at screening or established diagnosis of hepatitis C viral infection or is positive for hepatitis C antibody at the time of screening visit., Patient who has a laboratory abnormality at screening., History of hypersensitivity to any of the study drug constituents., Sexually active male unless he uses a condom during intercourse while taking drug and for 90 days after stopping investigational medication., Current or recent history (less than one year) of alcohol or drug abuse., Patient having received any other investigational drug within the preceding 30 days, or a longer and more appropriate time as determined by the Investigator (e.g., approximately five half-lives of the previous investigational drug)., Critical esophageal stricture or stricture not allowing the passage of a diagnostic upper endoscope (e.g., with an insertion tube diameter > 9mm)., Has a history of esophageal surgery or an esophageal dilation, Initiation or change of a food-elimination diet or introduction of a previously eliminated food group in the 6 weeks prior to screening. Patient on a food-elimination diet must remain on the same diet throughout the study period., Contraindicated for esophageal biopsy for any reason (e.g., presence of varices at endoscopy)., Current evidence of oropharyngeal or esophageal candidiasis or active infection with Helicobacter pylori., Commencement, cessation, or modification of the dosage schedule for allergen immunotherapy (oral or sublingual); participants maintaining a consistent dosage of these treatments for a minimum of one year before screening are eligible for inclusion in the study. However,
研究者
相似试验
进行中（未招募）
不适用
A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalised for volume overload and require intravenous diuretic therapy. - PROTECT {CKI-302}Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.MedDRA version: 9.1Level: LLTClassification code 10000803Term: Acute heart failureEUCTR2006-001637-18-SEovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)1,000
进行中（未招募）
不适用
A research study of a new drug (MT-102) for patients with weight loss and weakness (cachexia) related to lung or colorectal cancerCachexia related to stage III and IV non-small cell lung cancer and colorectal cancerMedDRA version: 14.1Level: LLTClassification code 10064015Term: Cancer cachexiaSystem Organ Class: 100000004861EUCTR2010-022486-10-DEPsioxus Therapeutics Limited129
进行中（未招募）
不适用
A multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of oral dosing with GW679769 (50 mg or 150 mg) for 3 consecutive days in conjunction with a single intravenous dose of ondansetron for the prevention of post-operative and post-discharge nausea and vomiting in at risk females undergoing laparoscopic/laparotomic surgical procedures.EUCTR2004-000369-37-DKGlaxoSmithKline Group of Companies411
进行中（未招募）
1 期
A multicentre, randomised, double-blind, placebo-controlled, parallel group, dose-response phase III A study to evaluate safety and efficacy of Prolonged Release (PR) OROS methylphenidate (18, 36 and 72 mg/day), with open-label extension, in adults with attention deficit/ hyperactivity disorder. - LAMDAAttention Deficit Hyperactivity Disorder (ADHD)Classification code 10003731EUCTR2004-000730-37-CZJanssen-Cilag Medical Affairs EMEA
进行中（未招募）
不适用
A multicentre, randomised, double-blind, placebo-controlled study of the effects of KW-3902 Injectable Emulsion on heart failure signs and symptoms and renal function in subjects with acute heart failure syndrome and renal impairment who are hospitalised for volume overload and require intravenous diuretic therapy. - PROTECT {CKI-301}Patients being admitted to hospital for acute heart failure (AHFS) with volume overload and renal impairment.MedDRA version: 9.1Level: LLTClassification code 10000803Term: Acute heart failureEUCTR2007-001407-37-CZovaCardia Inc (wholly owned subsidiary of Merck & Co. Inc)1,000